Fennec Prepared For Market As Pedmark Finally Gets FDA Nod

After successive CRLs in 2020 and 2021, the drug gained a broad label for hearing loss in children treated with cisplatin for localized, non-metastatic solid tumors.

Fennec received FDA approval for Pedmark in children with cisplatin-associated hearing loss • Source: Shutterstock

More from New Products

More from Scrip